Review and prospect of the comprehensive treatment of drug-resistant tuberculosis

doi:10.3969/j.issn.2095-3755.2014.03.001

Abstract

TANG Shen-jie.. Review and prospect of the comprehensive treatment of drug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Health , 2014, 3(3): 141-147. doi: 10.3969/j.issn.2095-3755.2014.03.001

References

[1]World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva:World Health Organization, 2013.
[2]唐神结. 耐药结核病防治手册. 北京:人民卫生出版社,2009:75-156.
[3]唐神结,许绍发,李亮. 耐药结核病学. 北京:人民卫生出版社,2014:126-287.
[4]唐神结,高文. 临床结核病学. 北京:人民卫生出版社,2011:191-200.
[5]唐神结. 结核病临床诊治进展年度报告(2011). 北京:人民卫生出版社,2012:51-91.
[6]唐神结. 结核病临床诊治进展年度报告(2012).北京:人民卫生出版社,2013:79-158.
[7]唐神结. 结核病临床诊治进展年度报告(2013).北京:人民卫生出版社,2014.
[8]World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva:World Health Organization, 2008.
[9]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. WHO/HTM/TB/2011.6. Geneva:World Health Organization,2011.
[10]中国防痨协会.耐药结核病化学治疗指南(2009).中国防痨杂志,2010,32(4):181-198.
[11]Chang KC,Yew WW,Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother,2011,55(10):4499-4505.
[12]Pierre-Audigier C,Surcouf C,Cadet-Daniel V,et al. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2012,16(2):221-223.
[13]刘一典,桂徐蔚,景玲杰,等.耐多药结核分枝杆菌临床分离株30株对氟喹诺酮类及二线注射类抗结核药敏感性的分析.中华临床医师杂志(电子版),2013,7(4):1565-1568.
[14]Tang S,Zhang Q,Yu J,et al. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand J Infect Dis,2011,43(4):280-285.
[15]姚岚,唐神结,肖和平,等. 利奈唑胺治疗广泛耐药结核病的临床疗效观察. 中华临床医师杂志(电子版),2010,4(12):2435-2440.
[16]Lew W,Pai M,Oxlade O,et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med,2008,149(2):123-134.
[17]Tabarsi P,Chitsaz E,Tabatabaei V,et al. Revised Category Ⅱ regimen as an alternative strategy for retreatment of Category Ⅰ regimen failure and irregular treatment cases. Am J Ther,2011,18(5):343-349.
[18]Bonnet M,Pardini M,Meacci F,et al. Treatment of Tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS One,2011,6(8):e23081.
[19]World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. WHO/HTM/TB/2013.2. Geneva:World Health Organization,2013.
[20]Winston CA,Mitruka K. Treatment duration for patients with drug-resistant tuberculosis, United States. Emerg Infect Dis,2012,18(7):1201-1202.
[21]Heller T, Lessells RJ, Wallrauch CG, et al.Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis,2010,14(4):420-426.
[22]唐神结,肖和平,张青.耐多药结核病化学治疗研究的新进展.中华结核和呼吸杂志,2009,32(8):617-620.
[23]Bang D, Lillebaek T, Thomsen V, et al.Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992—2007.Scand J Infect Dis,2010,42(4):288-293.
[24]Joseph P, Desai VB, Mohan NS, et al. Outcome of standar-dized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res, 2011,133: 529-534.
[25]Blumberg HM,Burman WJ,Chaisson RE,et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med,2003,167(4):603-662.
[26]Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993.
[27]Lee J, Lee CH, Kim DK,et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med, 2011, 26(2):153-159.
[28]唐神结,肖和平.利奈唑胺抗结核作用的研究及其最新进展. 中华临床医师杂志(电子版),2010,4(1):63-66.
[29]唐神结,肖和平.耐药结核病的化学治疗药物及其研究进展.中华医学杂志,2009,89(44):3160-3162.
[30]Cox N, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Turberc Lung Dis, 2012,16(4):447-454.
[31]Nuermberger EL, Spigelman MK,Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology,2010,15(5):764-778.
[32]Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet,2010,375(9731): 2100-2009.
[33]Zhang Y, Liu J, Wang Y, et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci, 2012, 55(9):800-806.
[34]Butov DA, Pashkov YN, Stepanenko AL, et al. Phase Ⅱb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines,2011,9:3.
[35]Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase Ⅰ Clinical Trial of the therapeutical antituberculous vaccine RUTI.Vaccine,2010,28(4):1106-1116.
[36]Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, 2013, 381(9871):1021-1028.
[37]唐神结,肖和平,李红,等.经皮肺穿刺注药治疗耐多药肺结核空洞的近远期疗效观察.中国防痨杂志,2009,31(2):94-99.
[38]唐神结,肖和平.肺结核的介入治疗.中国防痨杂志,2003,25(2):113-116.
[39]丁卫民, 傅瑜. 关于“气管支气管结核诊断和治疗指南(试行)”的几点补充说明. 中华结核和呼吸杂志,2013,36(2):159-160.
[40]丁卫民,傅瑜. 支气管结核的诊断治疗评价. 中国防痨杂志, 2011, 33(11): 697-702.
[41]中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行). 中华结核和呼吸杂志,2012,35(8):581-587.
[42]傅瑜, 初乃惠, 苑松林, 等. 介入疗法在耐多药肺结核综合治疗中的作用. 中华结核和呼吸杂志, 2008, 31(2): 95-98.
[43]丁卫民, 张广宇, 蔡青山, 等. 呼吸内镜介入治疗在结核病中的应用//唐神结. 结核病临床诊治进展年度报告(2012). 北京: 人民卫生出版社, 2013:98-106.
[44]张广宇, 杨楠, 李洪敏,等. 抗结核药物凝胶介质肺内应用安全性评价. 国际呼吸杂志,2009,29(8):467-469.
[45]宫希涛,刘玉峰,田红. 经支气管镜注药辅助治疗耐多药肺结核临床研究.中国内镜杂志,2012,18(6):647-649.
[46]朱友生,唐神结,吴征斌,等.化疗加人工气腹治疗耐多药肺结核的研究. 中华结核和呼吸杂志,2001,24(6):384.
[47]于大平,傅瑜.耐多药肺结核133例外科治疗效果探讨. 中华结核和呼吸杂志,2009,32(6):450-453.
[48]窦学军,龚昌帆,闫东杰,等. 手术联合化疗治疗耐多药肺结核结果分析. 中国防痨杂志,2007, 29(4):336-338.
[49]宋言峥,王旭,刘保池,等. 结核病灶内定点清除术的临床应用.中华结核和呼吸杂志,2012,35(5):380-381.
[50]Man MA, Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg,2012,42 (1):e9-12.
[51]秦世炳, 董伟杰, 兰汀隆,等.128例脊柱结核耐药患者的临床分析.中国防痨杂志, 2013,35(5): 299-304.
[52]张嘉利,李大伟,马远征,等.多节段胸腰椎脊柱结核外科治疗的回顾性研究.中国防痨杂志, 2013, 35(5): 305-308.
[53]范俊, 秦世炳, 董伟杰,等. 经病椎置入短椎弓根螺钉后路内固定融合术治疗多椎体结核临床疗效观察.中国防痨杂志, 2014,36(8): 666-670.
[54]唐恺, 董伟杰, 兰汀隆, 等.一期后路病灶清除植骨内固定治疗上胸椎结核.中国防痨杂志, 2014,36(8): 675-678.
[55]薛海滨, 张聪, 顾苏熙, 等. 保守方法治疗脊柱结核的适应证和疗效分析.中国防痨杂志, 2014,36(8): 684-690.